No Data
No Data
Part 2 of the stocks that moved the previous day include Ise Chemical Industries, River Eletech, Dai Communications, etc.
Stock Name <Code> 11 Day Closing Price ⇒ Compared to Previous Day Eisai <4523> 6649-223: news of approval recommendation for Donanemab gumi <3903> 331-10: negative view following last weekend's earnings announcement CyberAgent <4751> 930.6-23.7: announcement of free live streaming of UEFA EURO 2024 including other news capcom co., ltd. <9697> 2915-61.5: backlash of stock price increase from the second half of the month rakuten group <
TRaaS On Product: Quarterly Report - 31st Quarter (2024/02/01 - 2024/04/30)
TRaaS On Product: Confirmation letter
Stocks that moved the day before, part 2: Hitachi, Mitsubishi Electric, Sun Electronics, etc.
Stock Name<Code> 10-day closing price⇒compared to yesterday Money Forward <3994> 5042 -176 Asset Management ONE's shareholding ratio declined. Sansan <4443> 1603 -45 Even among small and medium-sized growth stocks, it stood out with insignificant movements. Gumi <3903> 341 -5 It is negatively viewed due to a significant deficit in the previous period and a decline in dividends. ACCESS <4813> 1384 -151 There is a feeling of completion even for the rebound after the earnings report. Solasta <6197> 461 -14 Nomura
The TOPIX has continued to rise and has remained flat within a narrow range after a rebound.
Tokyo Stock Exchange's Growth Market Index 807.78 +6.27/Volume 142.69 million shares/Trading value 133 billion yen Tokyo Stock Exchange Growth Market 250 Index 625.78 +4.14/Volume 84.77 million shares/Trading value 81.6 billion yen Today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index continue to rise. The number of rising stocks is 359, the number of falling stocks is 180, and unchanged stocks are 33. In the US market on the 7th, the Dow Jones Industrial Average was down 87.18 dollars to 38798.99 dollars.
Emerging Markets Digest: Trace OP significantly decreased, while J Frontier sharply increased.
<4881> Fanpeppu 176 +17 sharply rose. Buying is expected for the future progress due to the announcement that FPP004X, an allergy vaccine under development, is targeting the first quarter of the 25th year-end for the start of Phase 1 clinical trials after the end of trading on the 7th. The company has signed an option agreement with Shionogi & Co., Ltd. for FPP004X and has the option to acquire exclusive research and development and commercialization rights for all diseases worldwide.
No Data